IMFINZI Durvalumab Reduces Death Risk in Limited-Stage Small Cell Lung Cancer Trial

IMFINZI Durvalumab - A Game-Changer in Cancer Treatment

IMFINZI ® (durvalumab) has achieved a significant milestone in cancer treatment by showcasing a survival benefit in limited-stage small cell lung cancer in a global Phase III trial.

Key Highlights:

• First and Only: IMFINZI is the pioneering immunotherapy to exhibit survival advantages in this cancer subtype.
• 27% Reduction in Death Risk: The trial results demonstrated a remarkable decrease in mortality risk compared to placebo.

This groundbreaking advancement underscores the importance of immunotherapy in reshaping the landscape of cancer treatment, offering new hope and possibilities for patients.